News

Soligenix vaccine for Sudan ebolavirus demonstrates 100 percent protection in primate testing

Results from non-human primate testing of a Soligenix, Inc.-developed Bivalent Thermostabilized Filovirus vaccine, released this week, suggested 100 percent protection provided against the Sudan ebolavirus among dosed non-human primates.

The single vial vaccine is meant to target both the Marburg and Sudan filoviruses, and its antigens and adjuvants have been previously shown to shield primates from subsequent infection. Developed in collaboration between Soligenix and the University of Hawaiʻi at Mānoa (UH), the successful showing raised hopes among researchers that the associated vaccine platform could mean larger things still for the U.S. government’s overall pandemic preparedness efforts.

Currently, no vaccine exists for either Sudan ebolavirus or Marburg marburgvirus.

“Filoviruses such as Zaire ebolavirus, Sudan ebolavirus, and Marburg marburgvirus are some of the most lethal viruses known, and they are endemic in areas of the world where the power supply and distribution network can be uncertain,” Dr. Axel Lehrer, associate professor with UHM’s Department of Tropical Medicine, Medical Microbiology and Pharmacology, said. “A heat stable vaccine in a single vial format would significantly enhance any public health preparedness or response to a new outbreak, at its source. Our work to date has demonstrated the feasibility of rapid and efficient manufacturing, as well as the ability to thermostabilize multiple antigens that can then be stored at temperatures exceeding 100 degrees Fahrenheit. Having a vaccine platform available such as this has the potential to accelerate worldwide vaccination campaigns addressing future health emergencies, including another global pandemic like the one we are unfortunately experiencing with COVID-19.”

The milestone for deployment against these filoviruses is that it shows the platform can still provide complete protection with a thermostabilized formulation, increasing its viability worldwide.

The same vaccine platform deployed against these filoviruses was also used to develop CiVax, a COVID-19 vaccine that showed some immunogenicity against previous disease variants. Soligenix intends to test that vaccine candidate against the newly emerged Omicron variant.

“Our next generation combined vaccine platform includes three major components: a robust protein manufacturing process that has been demonstrated on multiple protein antigens, a novel nano-emulsion adjuvant which induces broad immunity, and a formulation procedure which enables thermostabilization of the combination of adjuvant and antigen in a single vial,” Dr. Oreola Donini, senior vice president and Chief Scientific Officer of Soligenix, said. “Elements of this vaccine platform have been utilized in our ricin toxin, filovirus, and COVID-19 vaccine candidates, indicating its broad applicability.”

Chris Galford

Recent Posts

Sen. Barrasso raises concerns over DOE’s ability to protect AI R&D from China

With artificial intelligence (AI) the increasing focus of interest for Washington and private companies, U.S.…

22 hours ago

Senate advances legislation that emphasizes federal building security

The Senate greenlit the Federal Building Security Act (S. 3613) this week, moving to the…

22 hours ago

Senate bill seeks to compel national security risk analysis of economic integration with China

A bipartisan group of senators recently introduced the American Economic Independence Act, which would require…

2 days ago

Sen. Peters presses federal agencies to increase cybersecurity for American health care

Citing cases where cyberattacks targeted health care systems in the United States, U.S. Sen. Gary…

2 days ago

U.S. Justice Department launches National Extreme Risk Protection Order Resource Center to curb gun violence

The U.S. Department of Justice recently launched a new resource center – the National Extreme…

3 days ago

Government funding agreement includes $3M allotment to create Northern Border security center

Among the provisions included in the recent $1.2 trillion funding agreement signed by President Joe…

3 days ago

This website uses cookies.